



Drug Formulary Update, October 2019 State Programs

Updates to the HealthPartners State Programs Formulary are listed below.

Please see www.healthpartners.com/formularies for details.

All updates are effective October 1.

Drug name	Current Status	New Status	Effective Date	Comments
Abatacept (Orencia)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Abiraterone (Yonsa)	NF-PA, SP Oncology	NF-PA TD, SP Oncology	10/1/2019	Adding to the Trial Drug Program.
Abiraterone (Zytiga Brand)	NF-PA TD, SP Oncology	NF-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Abiraterone (Zytiga generic) 250mg	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Acalabrutinib (Calquence)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Accu-Chek Guide	Not Covered	Covered	10/1/2019	
Adalimumab (Humira)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Afatinib (Gilotrif)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Albuterol HFA (Ventolin generic)	F PA	F	10/1/2019	
Albuterol HFA (Ventolin)	F	F PA	10/1/2019	Adding PA criteria.
Alectinib (Alecensa)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Aliskiren (Tekturna)	F	F PA	10/1/2019	Adding PA criteria.
Alosetron (Lotronex)	NF PA	NF PA	10/1/2019	Updating PA criteria.
Alpelisib (Piqray)		NF-PA-QL, SP	10/1/2019	A new FDA approval.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Amifampridine (Firdapse)	F-PA-QL, SP	NF-PA-QL, SP	10/1/2019	Removing from formulary, and updating PA criteria.
Amifampridine (Ruzurgi)		F-PA-QL, SP	10/1/2019	A new FDA approval.
Apremilast (Otezla)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Axitinib (Inlyta)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Benzonatate (Tessalon)	F	NF	10/1/2019	
Bexarotene (Targretin Brand and generic)	NF-PA TD, SP Oncology	NF-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Binimetinib (Mektovi)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Brigatinib (Alunbrig)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Bupropion XL (Wellbutrin XL)	NF-PA	NF-PA	10/1/2019	Updating PA criteria.
Cabozantinib (Cabometyx)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Cabozantinib (Cometriq)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Camrese (Seasonique generic)	NF PA	F	10/1/2019	
Camrese Lo (Lo Seasonique generic)	NF PA	F	10/1/2019	
Canakinumab (Ilaris)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Carbamazepine XR (Tegretol XR)	F	F PA	10/1/2019	Adding PA criteria.
Ceritinib (Zykadia)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Certolizumab (Cimzia)	F-PA-QL, SP	F-PA-QL, SP	10/1/2019	Updating quantity limit, to FDA-maximum dosing.
Chlorzoxazone (Lorzone)	NF AE	NC	10/1/2019	
Cladribine (Mavenclad)		F SP PA	10/1/2019	A new FDA approval.
Clobazam (Sympazan)		NF	10/1/2019	A new FDA approval.
Cobimetinib (Cotellic)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Crizotinib (Xalkori)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Dabrafenib (Tafinlar)	F-PA TD, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Dacomitinib (Vizimpro)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Dalfampridine (Ampyra Brand)	NF-PA, SP	NF-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Dalfampridine (Ampyra generic)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Dexcom continuous glucose monitoring system	Covered	Covered ST	10/1/2019	Adding criteria, reserving for those at a higher risk of hypoglycemia including those on short-acting insulin or a sulfonylurea.
Dolutegravir/lamivudine (Dovato)		NF	10/1/2019	A new FDA approval.
Duvelisib (Copiktra)	F-PA, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing, and adding to the Trial Drug program.
Enasidenib (Idhifa)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Encorafenib (Braftovi)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Epinephrine 0.3 mg auto-inject	F	F PA	10/1/2019	Teva Manufacturer only
Erdafitinib (Balversa)		NF-PA, SP Oncology	10/1/2019	A new FDA approval.
Erlotinib (Tarceva generic)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Erlotinib (Tarceva Brand)	NF-PA TD, SP Oncology	NF-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Etanercept (Enbrel)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Everolimus (Afinitor)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Fenofibrate 160 mg	F	F PA	10/1/2019	Adding PA criteria.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Filgrastim (Granix)	F, SP Oncology	F, SP	10/1/2019	Removing from Oncology Program.
Filgrastim (Neupogen)	F, SP	NF-PA, SP	10/1/2019	Removing from formulary, and adding PA criteria.
Filgrastim (Zarxio)	F, SP	NF-PA, SP	10/1/2019	Removing from formulary, and adding PA criteria.
Fluticasone/ salmeterol (Advair Diskus)	F	F PA	10/1/2019	
Fluticasone/ salmeterol (Wixela)	F PA	F	10/1/2019	
Formoterol (Foradil)	F	NF	10/1/2019	
Freestyle Libre continuous glucose monitoring system	Covered	Covered ST	10/1/2019	Adding criteria, reserving for those at a higher risk of hypoglycemia including those on short-acting insulin or a sulfonylurea.
Galcanezumab (Emgality) 100 mg/ml		F-PA-QL, SP	10/1/2019	A new strength.
Gefitinib (Iressa)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Gilteritinib (Xospata)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Glasdegib (Daurismo)	F-PA, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing, and adding to the Trial Drug program.
Golimumab (Simponi)	NF-PA, SP	NF-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Guanfacine ER	F PA QL	F QL	10/1/2019	
Ibrutinib (Imbruvica)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Idelalisib (Zydelig)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Insulin lispro (Humalog generic), pen and vial	F	F PA	10/1/2019	
Interferon beta 1b (Extavia)	NF-PA-QL, SP	NF-PA-QL, SP	10/1/2019	Updating quantity limit.
Irbesartan	F PA	F	10/1/2019	
Irbesartan-HCTZ	F PA	F	10/1/2019	

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Ivermectin (Sklice) lotion	F	F PA	10/1/2019	Adding PA criteria.
Ivosidenib (Tibsovo)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Ixazomib (Ninlaro)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Ixekizumab (Taltz)	NF-PA, SP	NF-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Lapatinib (Tykerb)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Larotrectinib (Vitrakvi)	F-PA-QL, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding to the Trial Drug Program.
Lenalidomide (Revlimid)	F, SP Oncology	F-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Lenvatinib (Lenvima)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Lorlatinib (Lorbrena)	F-PA, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing, and adding to the Trial Drug program.
Mepolizumab (Nucala)		F-PA, SP	10/1/2019	A new self-administered dosage form.
Methylphenidate CD (Metadate CD Brand)	F QL	NF QL	10/1/2019	
Methylphenidate CD (Metadate CD generic)	F PA QL	F QL	10/1/2019	
Neratinib (Nerlynx)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Niraparib (Zejula)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Omacetaxine (Synribo)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Osimertinib (Tagrisso)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Panobinostat (Farydak)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Pazopanib (Votrient)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Pomalidomide (Pomalyst)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Ponatinib (Iclusig)	F-PA, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing, and adding to the Trial Drug program.
Povidone/hyaluronate/glycyrrhetic acid (Gelclair) gel	NF	Not Covered	10/1/2019	
Procarbazine (Matulane)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Riociguat (Adempas)	F-PA, SP	F-PA, SP	10/1/2019	Update PA criteria.
Risankizumab (Skyrizi)		NF-PA, SP	10/1/2019	A new FDA approval.
Rucaparib (Rubraca)	NF-PA TD, SP Oncology	NF-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Ruxolitinib (Jakafi)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Salicylic acid (Keralyt) 6% gel	NF	Not Covered	10/1/2019	
Siponimod (Mayzent)		F SP QL	10/1/2019	A new FDA approval.
Sonidegib (Odomzo)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Sorafenib (Nexavar)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Stiripentol (Diacomit)		F-PA-QL, SP	10/1/2019	A new FDA approval
Sunitinib (Sutent)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Tafamidis (Vyndaqel)		F SP PA	10/1/2019	A new FDA approval
Talazoparib (Talzenna)	NF-PA, SP Oncology QL	NF-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing, and adding to the Trial Drug program.
Telmisartan tablet	NF	F PA	10/1/2019	Adding with PA criteria.
Tezacaftor/ ivacaftor (Symdeko)	F-PA, SP	F-PA, SP	10/1/2019	Update PA criteria.
Tofacitinib (Xeljanz)	NF-PA-QL, SP	NF-PA-QL, SP	10/1/2019	Updating quantity limit.
Trametinib (Mekinist)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Trifluridine/ tipiracil (Lonsurf)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Vandetanib (Caprelsa)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Vemurafenib (Zelboraf)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Venetoclax (Venclexta)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Vismodegib (Erivedge)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Vorinostat (Zolinza)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Zolpidem tablet	F	F AE QL	10/1/2019	Elderly patients (>= age 65) will be limited to #20 tablets per prescription.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program